Skip to content
10-K

Annual Report

Sunshine Biopharma Inc. SBFM SBFMW

0001683168-26-002644

← back to feed
Filed
Apr 3, 2026 12:00 AM ET
Period of report
Restated figures. One or more values in this filing restate previously reported amounts.

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding FY 2025 · Apr 2, 2026 4.91M sh
Stock Repurchased FY 2025 · Dec 31, 2025 $0
Stock Repurchased FY 2025 · Dec 31, 2024 $3.14M
Capex FY 2025 · Dec 31, 2025 $174.49K
Capex FY 2025 · Dec 31, 2024 $1.66M
Operating Cash Flow FY 2025 · Dec 31, 2025 −$5.33M
Operating Cash Flow restated FY 2025 · Dec 31, 2024 −$12.52M
Stockholders Equity FY 2025 · Dec 31, 2025 $23.04M
Stockholders Equity FY 2025 · Dec 31, 2024 $23.5M
Stockholders Equity FY 2025 · Dec 31, 2023 $21.21M
Current Liabilities FY 2025 · Dec 31, 2025 $6.44M
Current Liabilities FY 2025 · Dec 31, 2024 $6.31M
Total Liabilities FY 2025 · Dec 31, 2025 $7.04M
Total Liabilities FY 2025 · Dec 31, 2024 $7.06M
Current Assets FY 2025 · Dec 31, 2025 $26.85M
Current Assets FY 2025 · Dec 31, 2024 $25.97M
Total Assets FY 2025 · Dec 31, 2025 $30.08M
Total Assets FY 2025 · Dec 31, 2024 $30.56M
Eps Basic FY 2025 · Dec 31, 2025 −$1.44
Eps Basic FY 2025 · Dec 31, 2024 −$7.32
Sga Expense FY 2025 · Dec 31, 2025 $18.48M
Sga Expense FY 2025 · Dec 31, 2024 $16.48M
Rd Expense FY 2025 · Dec 31, 2025 $604.31K
Rd Expense FY 2025 · Dec 31, 2024 $933.9K
Net Income FY 2025 · Dec 31, 2025 −$5.98M
Net Income FY 2025 · Dec 31, 2024 −$5.13M
Operating Income FY 2025 · Dec 31, 2025 −$6.23M
Operating Income FY 2025 · Dec 31, 2024 −$5.81M
Gross Profit FY 2025 · Dec 31, 2025 $12.26M
Gross Profit FY 2025 · Dec 31, 2024 $10.67M
Cost Of Revenue FY 2025 · Dec 31, 2025 $24.05M
Cost Of Revenue FY 2025 · Dec 31, 2024 $24.2M
Revenue FY 2025 · Dec 31, 2025 $36.31M
Revenue FY 2025 · Dec 31, 2024 $34.87M